CRNX (Crinetics Pharmaceuticals) Research & Development: $355.90 Mil (TTM As of Mar. 2026)


CRNX Crinetics Pharmaceuticals Inc CRNX
47 GF Score
Price $37.80
GF Value $678.51
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Crinetics Pharmaceuticals Research & Development?

Crinetics Pharmaceuticals CRNX +2.41% 47 Research & Development is $355.90 Mil as of Mar. 2026. GuruFocus rates CRNX with a GF Score™ of 47/100 and a GF Value™ of $678.51 (Possible Value Trap). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Crinetics Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was $100.08 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $355.90 Mil.

Crinetics Pharmaceuticals  (NAS:CRNX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Crinetics Pharmaceuticals Research & Development Related Terms

Crinetics Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Crinetics Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crinetics Pharmaceuticals Research & Development Chart

Crinetics Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 84.26 130.23 168.53 240.16 332.06

Crinetics Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.24 80.30 90.46 85.05 100.08
CRNX
47GF Score
Crinetics Pharmaceuticals Inc CRNX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crinetics Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $355.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $355.90 Mil mean?
Crinetics Pharmaceuticals (CRNX) has a Research & Development of $355.90 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Crinetics Pharmaceuticals and its competitors.
Is Crinetics Pharmaceuticals' Research & Development too high?
Crinetics Pharmaceuticals' current Research & Development is $355.90 Mil. Overall, Crinetics Pharmaceuticals has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Crinetics Pharmaceuticals' Research & Development compare to CPRX and NAMS?
Crinetics Pharmaceuticals' Research & Development of $355.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Crinetics Pharmaceuticals and its competitors. Crinetics Pharmaceuticals's current Research & Development is $355.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crinetics Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals (CRNX) is currently considered Possible Value Trap. The stock's GF Value™ is $678.51, compared to a current price of $37.80 — trading 94.4% below its estimated fair value. The current Research & Development is $355.90 Mil. Crinetics Pharmaceuticals' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Crinetics Pharmaceuticals (CRNX), the current Research & Development is $355.90 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Crinetics Pharmaceuticals (CRNX) Overvalued in 2026?

Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued. The current stock price of $37.80 is trading 94.4% below its estimated GF Value™ of $678.51. GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.

Key valuation signals for CRNX:

  • Research & Development: $355.90 Mil
  • GF Value™: $678.51 vs. price of $37.80 (94.4% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the CRNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Crinetics Pharmaceuticals Business Description

Other Exchanges 6Z4:Germany
Address 6055 Lusk Boulevard, San Diego, CA, USA, 92121
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
47GF Score

Get the complete analysis for CRNX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.80
Price
$678.51
GF Value